HealthMore in Health→
Roche and C4 Therapeutics Deepen Their Bet on DACs
Roche is expanding work with longtime partner C4 Therapeutics in a deal worth $20 million upfront, underscoring rising interest in degrader-antibody conjugates as a new twist on an already hot cancer-drug category.
Key Takeaways
- Roche is expanding work with C4 Therapeutics in a DAC-focused deal worth $20 million upfront.
- Endpoints says DACs are gaining traction as a degrader-based variation on antibody-drug conjugates.
DE
DT Editorial Team··via endpoints.news